Astrazeneca plc AZN.US Overview
AZN AI Analysis & Strategy
Analysis Conclusion
The stock holds a moderate value rating. If you have positions, consider retaining; for new ones, wait for a value score above 4.
AZN Current Performance
-1.14%
Astrazeneca plc
-0.35%
Avg of Sector
-0.22%
S&P500
AZN Key Information
AZN Financial Forecast
Unit : USD
AZN Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 1.24 | 20.4% | 12.7% | 13.59B | 7.2% | -3.3% | 10.1% |
| 2024Q3 | 1.05 | 43.8% | -1.9% | 14.89B | 23.8% | 11.6% | 10.5% |
| 2024Q2 | 1.04 | 19.5% | 1% | 13.57B | 18% | 3.6% | 14.9% |
| 2024Q1 | 0.99 | -8.3% | -17.5% | 12.94B | 13.3% | -1.1% | 17.2% |
| 2023Q4 | 1.03 | 7.3% | -15.6% | 12.68B | 16.5% | 7.5% | 8% |
AZN Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.